HCQ clinical trials will resume: WHO
The World Health Organisation said on Wednesday that clinical trials of the drug hydroxychloroquine will resume, after having been suspended pending a safety review in the search for coronavirus treatments.
- Hydroxychloroquine — which has anti-inflammatory and antiviral properties — inhibited the coronavirus in laboratory experiments, but has not been proven effective in humans, particularly in placebo-controlled, randomised clinical trials considered the gold standard for data.
- The debate has become highly politicised, and many scientists have voiced concern.
- Nearly 150 doctors signed an open letter to The Lancet last week calling the article’s conclusions into question and asking to make public the peer review comments that preceded publication.
- The study, using data provided by healthcare data analytics firm Surgisphere, was not a traditional clinical trial that would have compared hydroxychloroquine to a placebo or other medicine.
- The Lancet’s editors said in a note that serious scientific questions about the study were brought to their attention and an independent audit of the data has already been commissioned.